InnoCare Pharma’s Post

British Journal of Cancer recently published a paper entitled "Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumors with on-target resistance to first-generation agents". The journal concluded that zurletrectinib is a novel, highly potent next-generation TRK inhibitor with stronger in vivo brain penetration and intracranial activity than other next-generation agents. Check out the full release: https://lnkd.in/etUEhqYJ Check out the full paper: https://lnkd.in/eWzJMD-u

📹 In this must-watch video, UROONCO PCa associate editor Dr. Pawel Rajwa speaks to Prof. Bertrand Tombal and Prof. Nick James on the management of synchronous metastatic hormone sensitive prostate cancer (mHSPC). They discussed treatment options such as androgen deprivation therapy (ADT) with Radium-223 or abiraterone; compared doublet and triplet therapy; examined the role of ADT; and shared their predictions in the future of mHSPC treatment. Watch the full video here 👇 https://lnkd.in/d2kWsZ5u

🔊 Latest news!   🔬Knockdown of FAM3C inhibits breast cancer tumour growth Researchers from the Ulsan National Institute of Science and Technology (UNIST) discover that inhibition of FAM3C expression in cancer-associated adipocytes during early tumour development holds promise as a novel treatment approach. Click on the link in the comments to read more 👇   #FAM3C #adipocytes #cancer

Cancer Early Diagnosis #ISET detects circulating #tumour cells (CTCs). CTCs are isolated by mechanical filtration. Using cytology, it is possible to identify which organ they come from. This detection happens even if the imaging detects nothing. ISET allows the detection of tumours at very early stages. CTCs are the tumor cells, that circulate in the blood, that are responsible for future metastases. Unlike other methods, ISET does not produce false negatives or false positives. https://lnkd.in/de3P4-Bn. Book - Patrizia Paterlini Bréchot - Matar o Cancro Founder and President at Rarecells, Professor at Université de Paris https://lnkd.in/dkmNnTTi #cancer #ctc #ccc #cancerdetection #cancerdiagnosis

Excited to see this new study with Cold Plasma demonstrating its synergistic effects for cancer cell apoptosis when treating solid tumors in conjunction with known chemotherapeutic agents. It is known plasma can either promote apoptosis or cell proliferation depending on the dose (gas flow, time plume is in contact with surface, etc.). This study demonstrated the importance of optimization when working with cold plasma that is critical depending on the goal of treatment: grow or kill. For example, in the study, cell viability of Ewing sarcoma cell lines was significantly lower when treated with cold plasma for 20 seconds vs 10 seconds in conjunction with chemo. It is exciting to see cold plasma employed as an adjuvant for cancer treatments and I look forward to seeing more promising studies like this one! #ewingsarcoma #coldplasma #solidtumors #adjuvant #cancer

Certain patients may not benefit from the addition of immunotherapy in locally advanced triple negative breast cancer, but biomarkers to identify these patients are yet to be discovered. Our study published in the Journal of Precision Medicine highlights that a comprehensive evaluation of the tumor immune microenvironment can potentially help select patients who are most likely to benefit from the addition of immunotherapy to chemotherapy in the neoadjuvant setting. #OmniSeqInsight #Biomarkers #Cancer #NGS #TumorMicroenvironment

A new paper by Dr. Matthew Galsky, published in Cell Press, shows that urothelial cancer patients with tumors showing preexisting adaptive immunity benefit more from atezolizumab combined with gemcitabine and cisplatin (GemCis) versus gemcitabine and carboplatin (GemCarbo). Read the paper: https://mshs.co/3vRfHlK #Cancer #Research #GU24

Are you using liquid biopsy to its potential? Learn from a panel of experts as they share information and perspectives about biomarker testing guidelines and the biomarker ctDNA tumor fraction reported by Foundation Medicine’s liquid biopsy test. Register today for our Foundation Frontiers webinar on advanced prostate cancer at the link here: https://bit.ly/4fHQWL5

Are you using liquid biopsy to its potential? Learn from a panel of experts as they share information and perspectives about biomarker testing guidelines and the biomarker ctDNA tumor fraction reported by Foundation Medicine’s liquid biopsy test. Register today for our Foundation Frontiers webinar on advanced prostate cancer at the link here: https://bit.ly/4fHQWL5